Compare Novartis AG (NVS) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Global X Uranium ETF — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Global X Uranium ETF trades at $40.59. The key difference: Novartis AG pays a 3.17% dividend while Global X Uranium ETF pays none, and Novartis AG is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| NVS | URA | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $168.62 | $61.81 |
52-Week Low | $113.50 | $36.45 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
